Barrington raised the firm’s price target range on Paysign (PAYS) to $8-$9 from a prior range of $6-$7 and keeps an Outperform rating on the shares. The firm cites the “strong outlook” for Paysign’s Patient Affordability segment for the pharmaceutical industry for its target hike.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
- Strategic Positioning and Growth Potential: PaySign’s Role in Pharmaceutical Patient Affordability
- Paysign price target raised to $9 from $7 at Lake Street
- Paysign management to meet with Lake Street
- DA Davidson research director holds a bison roundup conference call
- 3 Best Stocks to Buy Now, 6/16/2025, According to Top Analysts